• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

US pays Moderna $176m to develop bird-flu jab

Mary Wilson

Well-known member
2 days ago
By Michelle Roberts, Digital health editor, BBC News​

The US government has given Moderna $176m (£139m) to develop a messenger-ribonucleic-acid-based (mRNA) pandemic influenza vaccine that would work against bird flu.

It says it wants to be "better prepared" for public-health crises, having learned lessons from Covid.

Bird flu is not a big threat to people, despite outbreaks in poultry and cattle.

But experts want a working vaccine that could be quickly rolled out, in case the virus mutates and becomes a problem.

Vaccines using mRNA technology - which the Moderna's Covid jab is also based on - can be produced more quickly.

And the US government says adding this technology to its pandemic-flu toolkit enhances its ability to be "nimble and quick" against bird flu.

The $176m, from the US Biomedical Advanced Research and Development Authority, will be used to complete late-stage development and testing of Moderna's vaccine against H5N1 avian influenza. ...

The results, expected later this year, will inform the next steps, it says. ...

https://www.bbc.com/news/articles/c51ywpxp43lo

 
Back
Top